Live life again
Transforming kidney transplantation outcomes through improved prevention of CMV disease
We strive to improve the quality of life of transplant recipients
Transplantation is intended to give patients their life back. However, an infection with cytomegalovirus (CMV), triggered by post-transplant immunosuppression, may be devastating to patient outcomes. SYN002 is aimed at improving the life of patients and their ability to enjoy a normal life after transplantation, by reducing the risk of CMV reactivation through treatment of the donor organ (ex vivo) prior to transplantation.
We strive to improve the quality of life of transplant recipients
Transplantation is intended to give patients their life back, but an infection with cytomegalovirus (CMV) triggered by the transplant conditioning therapy may be devastating to patient outcomes. SYN002 is aimed at improving the life of transplant patients and ensure their ability to enjoy a normal life after transplantation by eliminating the risk of CMV infection in transplant recipients, either by treating the donor organ (ex vivo) prior to transplantation or by treating the recipient after transplantation (in vivo).
Transplantations give patients a second chance at life
Organ donations give seriously ill patients a second chance at life. Children and young people return to school, and adults can often resume work and live life again
CMV can be devastating for transplant recipients
Despite standard antiviral prophylaxis after transplantation, CMV reactivation remains a significant risk for recipients of CMV-positive donor organs, potentially leading, rehospitalisation and increased morbidity. Current treatments are lengthy, carry side effects and do not address the latent CMV infection.
We protect the investment in quality of life for transplant recipients
By significantly reducing both latent and active CMV infection prior to transplantation, Synklino aims at increasing the chances of better clinical outcomes for patients, so they quickly move forward and enjoy their new life after kidney transplantation.
What is Cytomegalovirus (CMV)?
CMV is a β-herpesvirus. Like all herpesvirus, CMV establishes life-long latent infection and is found in more than 60% of adults worldwide. There is currently no treatment that can eradicate CMV. Once you have been infected with CMV, the virus establishes latency (a dormant state) from where it may re-activate and cause an active lytic infection.
Normally, a healthy person’s immune system keeps the virus from causing illness and most people will never know they have CMV.
» I have three pairs of new running shoes and new running clothes to put in the closet. It is my belief that it will be good again when I get a new kidney
— (Quote from a patient waiting for a kidney transplantation)
Synklino in the news

Synklino announces first patient dosed in Phase 1 trial of SYN002 for CMV prevention in kidney transplantation
Synklino A/S, a clinical-stage biotechnology company developing a first-in-class, ex vivo therapy to transform kidney transplantation outcomes through better CMV prevention, today announces the first patient has been dosed in a first-in-human Phase 1 clinical trial of SYN002 for the prevention of cytomegalovirus (CMV) reactivation in kidney transplant recipients.

Synklino announces publication in American Journal of Transplantation highlighting proof-of-concept for SYN002 in eliminating CMV in human kidneys
Synklino, a Danish biotech company developing drugs to treat chronic viral infections, has decided to focus the development of SYN002 on eliminating CMV in infected organs prior to transplantation (ex vivo).